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Research
the suitability of patients for discharge from
hospital.1 This has been shown to perform
similarly to or better than other scoring
systems, such as the CURB-65.2-4
A recently proposed scoring system,
SMART-COP, was developed in Australia
and validated in a variety of settings, includ-
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Objective:  To examine the performance in tropical northern Australia of SMART-COP, 
a simple scoring system developed in temperate Australia to predict the need for 
intensive respiratory or vasopressor support (IRVS) in pneumonia patients.
Design, setting and patients:  A prospective observational study of patients admitted 
to Royal Darwin Hospital in the Northern Territory with sepsis between August 2007 and 
2008. Chest x-rays were reviewed to confirm pneumonia, and each patient’s 
RT-COP score was assessed against the need for IRVS.
lts:  Of 206 patients presenting with radiologically confirmed pneumonia, 184 were 
le for inclusion. The mean age of patients was 50.1 years, 65% were Indigenous 
6% were men. Overall, 38 patients (21%) required IRVS, and 18 patients (10%) died 
ay 30. A SMART-COP score of  3 had a sensitivity of only 71% for predicting the 
 for IRVS and 67% for 30-day mortality. As the variables most strongly associated 
with IRVS were serum albumin level < 35 g/L (odds ratio, 6.8) and Indigenous status 
(odds ratio, 2.3), we tested a modified scoring system (SMARTACOP) that used a higher 
weighting for albumin and included Indigenous status. A SMARTACOP score of  3 had 
a sensitivity of 97% for IRVS and 100% for 30-day mortality.
Conclusions:  The SMART-COP score underestimates the severity of pneumonia in 
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tropical northern Australia, but can be improved by using locally relevant additions.isk
for
poR  stratification systems are useful determining hospital dischargelicies and antimicrobial therapy in
patients with pneumonia, and identifying
patients at risk of adverse outcomes. The
best known of these, the Pneumonia Sever-
ity Index, was primarily designed to assess
ing patients from North America, temperate
Australia and Scotland, but few from tropi-
cal areas.5,6 In contrast to previously devel-
oped tools, SMART-COP was designed to
identify patients requiring intensive sup-
portive care, and its use is being considered
for inclusion in version 14 of the Australian
Therapeutic guidelines: antibiotic (Jenny John-
stone, Editor, Therapeutic Guidelines Lim-
ited, personal communication).
The epidemiology of pneumonia is signif-
icantly different in tropical northern Aus-
tralia than in temperate regions — a high
proportion of patients are Indigenous and
the average age of patients is lower.7 Fur-
thermore, the pathogens implicated in
pneumonia are significantly different to
those identified in temperate latitudes.8-10
We examined the performance of the
SMART-COP scoring system in patients with
community-acquired pneumonia presenting
to our referral centre in tropical northern
Australia.
METHODS
Royal Darwin Hospital (RDH) is the only
tertiary referral hospital for the tropical North-
ern Territory and serves a population of about
150 000 spread across an area of over
500000 km2. We conducted a prospective
observational study of adult patients with
sepsis (infection plus at least two criteria for
systemic inflammatory response syndrome
[SIRS]11) admitted to RDH between August
2007 and May 2008. The study was approved
by the Human Research Ethics Committee of
the NT Department of Health and Families
and Menzies School of Health Research.
Inclusion criteria were at least two symp-
toms suggestive of pneumonia (new cough,
fever, rigors, chest discomfort, new-onset
dyspnoea) and a chest radiograph or com-
puted tomography scan taken within 24
hours of admission demonstrating acute
pneumonia. All chest radiographs were
reviewed by a radiologist and, where the
report was inconclusive or ambiguous,
radiographs were also viewed by an infec-
tious diseases physician. Exclusion criteria
were: immunosuppression,5 active orders
limiting life-sustaining treatment, and direct
admission to the intensive care unit (ICU).
We defined intensive respiratory support
as the need for non-invasive ventilatory
support or intubation and mechanical venti-
lation. Vasopressor support was the use of
dopamine, noradrenaline, adrenaline or
vasopressin for treatment of hypotension.
We calculated SMART-COP scores as
defined in the Australian Community-
Acquired Pneumonia Study (ACAPS) (Box
1).5 We used univariate logistic regression
analysis to examine the individual compo-
nents of the SMART-COP score against the
need for intensive respiratory or vasopressor
support (IRVS). We then assessed the per-
formance of the SMART-COP score and
evaluated several variations of it, primarily
on the basis of its negative predictive value
(NPV), because of the need to identify
patients who did not require IRVS and could
thus be safely managed in a general ward.
Statistical analysis was performed using
Intercooled Stata, version 10 (StataCorp,
College Station, Tex, USA). A significance
level of 0.05 was used.
RESULTS
During the study period, 246 patients were
admitted with sepsis and a clinical diagnosis
of pneumonia. Of these, 40 did not have
radiological evidence of pneumonia and 22
met exclusion criteria (immunosuppression,
10; active orders limiting life-sustaining
treatment, 9; direct admission to the ICU,
3), leaving 184 eligible patients (Box 2).
Of the total group, 111 patients (60%)
were in the low-risk SMART-COP group
(score  2), and 11 of these (10%) required
IRVS (Box 3, Box 4). As a predictor of need
for IRVS, a SMART-COP score of  3 had a
significantly lower sensitivity, NPV and area
under the receiver operator characteristic
curve (AUROC) in our RDH group than in
the ACAPS cohort (P 0.05, Box 5).JA • Volume 192 Number 3 • 1 February 2010 133
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new-onset confusion (odds ratio [OR], 22.0;
95% CI, 2.5–194.4) and serum albumin
level < 35 g/L (OR, 6.8; 95% CI, 2.9–15.9)
were the strongest predictors of the need for
IRVS (Box 6). However, confusion was
present in only six of the 184 patients (3%),
making it less clinically useful in predicting
those at risk of needing IRVS. Indigenous
status was also associated with the need for
IRVS (OR, 2.3; 95% CI, 1.0–5.5). Contrary
to expectations, none of the comorbidities
that were assessed were significantly associ-
ated with the need for IRVS (Box 6).
Given that the SMART-COP score per-
formed poorly at the low-risk end in the
RDH cohort, we designed and tested a mod-
ified score, SMARTACOP, which increased
the weighting for albumin to 2 points and
included Indigenous status as a variable
(Box 1). These changes improved the per-
formance of the scoring system, largely due
to better discrimination of patients in the
low-risk group. Of the 111 patients in this
group according to the SMART-COP score,
43 were recategorised as moderate risk, of
whom 10 (23%) required IRVS. The specifi-
city of both the SMART-COP and SMART-
ACOP scores was poor (Box 5), and thus
they should not be used for their positive
predictive value.
The SMART-COP score also had poor
sensitivity for predicting 30-day mortality:
2 Characteristics of RDH patients, compared with those from the ACAPS cohort
Characteristic RDH (n = 184)* ACAPS (n = 885)* P
Age in years, mean (SD) 50.1 (16.3) 65.1 (19.9) < 0.001
Male 103 (56%) 537 (61%) ns 
Indigenous 120 (65%) 10 (1%) < 0.001
Remote-dwelling 51 (28%) not reported
Hazardous alcohol use† 76/134 (57%)‡ 48 (5.4%) < 0.001
Chronic renal disease 33 (18%) 169 (19%) ns
Chronic liver disease 26 (14%) 32 (4%) < 0.001
Diabetes mellitus 42 (23%) 159 (18%) ns
Smoker 93/151 (62%)‡ 182 (21%) < 0.001
COPD 39 (21%) 238 (27%) ns
Gram-negative pathogen§ 31/57 (54%) 72/404 (18%) < 0.01
Required IRVS 38 (21%) 94 (11%) < 0.01
Died in the hospital 16 (8.7%) 41 (4.6%) 0.02
Died within 30 days 18 (9.8%) 50 (5.6%) 0.03
RDH = Royal Darwin Hospital. ACAPS = Australian Community-Acquired Pneumonia Study.5 ns = not 
significant. COPD = chronic obstructive pulmonary disease. IRVS = intensive respiratory or vasopressor 
support. * All data except age are number (%). † Defined as > 4 standard drinks/day for men and > 2 for 
women.12 ‡ Level of alcohol use not documented for 50 patients and smoking status not documented for 33 
patients. § Denominator is those with an identified pathogen from blood cultures or from purulent sputum 
with predominant growth of an organism seen on Gram stain. Of the 31 gram-negative pathogens in RDH 
patients, the most common were Haemophilus influenzae (7), Acinetobacter spp. (7), Burkholderia 
pseudomallei (7), and Escherichia coli (4). ◆
1 Definition of SMART-COP and 
SMARTACOP scores*
SMART-COP score Points
Systolic blood pressure < 90 mmHg 2
Multilobar CXR involvement 1
Albumin level < 35 g/L 1
Respiratory rate raised† 1
Tachycardia  125 beats/min 1
Confusion (new onset) 1
Oxygen low‡ 2
P — arterial pH < 7.35 2
SMARTACOP score Points
Systolic blood pressure < 90 mmHg 2
Multilobar CXR involvement 1
Albumin level < 35 g/L 2
Respiratory rate raised† 1
Tachycardia  125 beats/min 1
Aboriginal or Torres Strait Islander 1
Confusion (new onset) 1
Oxygen low‡ 2
P — arterial pH < 7.35 2
ACAPS interpretation of SMART-COP score
0–2 points Low risk of needing IRVS
3–4 points Moderate risk (1 in 8) of 
needing IRVS
5–6 points High risk (1 in 3) of needing 
IRVS
 7 points Very high risk (2 in 3) of 
needing IRVS
CXR = chest x-ray. ACAPS = Australian Community-
Acquired Pneumonia Study.5 IRVS = intensive 
respiratory or vasopressor support. PaO2 = partial 
pressure of oxygen. FiO2 = fraction of inspired 
oxygen.
* Calculated using the initial set of observations 
taken in the emergency department. † Calculated 
using age-adjusted cut-offs: age  50 years,  25 
breaths/min; age > 50 years,  30 breaths/min. 
‡ Calculated using age-adjusted cut-offs: age  50 
years, PaO2 < 70 or oxygen saturation  93 or PaO2/
FiO2 ratio < 333; age > 50 years, PaO2 < 60 or oxygen 
saturation  90 or PaO2/FiO2 ratio < 250. ◆
3 Patients in Royal Darwin Hospital cohort requiring IRVS, stratified by 
SMART-COP and SMARTACOP scores
Number IRVS 30-day mortality
SMART-COP
Low risk (0–2) 111 11 (10%) 6 (5%)
Moderate risk (3–4) 48 15 (31%) 4 (8%)
High risk (5–6) 22 10 (46%) 6 (27%)
Very high risk ( 7) 3 2 (67%) 2 (67%)
SMARTACOP
Low risk (0–2) 68 1 (2%) 0
Moderate risk (3–4) 59 14 (24%) 7 (12%)
High risk (5–6) 39 13 (33%) 4 (10%)
Very high risk ( 7) 18 10 (56%) 7 (39%)
IRVS = intensive respiratory or vasopressor support. ◆134 MJA • Volume 192 Number 3 • 1 February 2010
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COP score died (sensitivity, 67%), compared
with none with a low-risk SMARTACOP
score (sensitivity, 100%). The AUROC for
30-day mortality was 0.74 for SMART-COP
and 0.77 for SMARTACOP.
DISCUSSION
In this study, we have demonstrated that the
SMART-COP scoring system underestimates
the need for intensive supportive treatment
and the risk of death in a tropical Australian
population hospitalised for pneumonia.
Our study population differs substantially
from those involved in previous studies of
pneumonia risk. Compared with patients in
the ACAPS cohort used to derive the
SMART-COP score, patients in this study
were younger and more likely to be Indige-
nous, drink hazardous amounts of alcohol,
smoke, and have chronic liver disease. In
addition, the causative organism in those
with an identified pathogen was a gram-
negative bacillus in more than half the
patients in this study, compared with 18% in
the ACAPS study. More than 20% of our
patients required IRVS, compared with 11%
in the ACAPS study. This may account for a
proportion of the decrease in NPV for the
SMART-COP score in the RDH cohort com-
pared with the ACAPS cohort, but is
unlikely to be solely responsible for the
observed difference in NPV.
Low serum albumin level appears to be
more strongly associated with the require-
ment for IRVS in this study than in the
original derivation study. Albumin decreases
in response to acute inflammation13,14 and
thus may be a surrogate marker for late
presentation, as well as severity of inflamma-
tion. Chronic liver disease and poor nutri-
tion associated with hazardous alcohol
intake may also be contributors to low
serum albumin levels.
We found Indigenous status to be associ-
ated with the requirement for IRVS and with
mortality. It is likely that Indigenous status is
a surrogate marker for poor health and
social disadvantage,15 and these factors are
likely to contribute more to poor outcomes
than any possible genetic susceptibility. Haz-
ardous levels of alcohol use were present in
the majority of Indigenous patients in this
study; however, this was not a risk factor for
IRVS or mortality. For pneumonia generally,
it is likely that an interaction between severe
infection and decreased physiological
reserve due to multiple underlying comor-
bidities is what puts an individual patient at
risk.
An alternative strategy to improve the
performance of the SMART-COP scoring
system would be to change the cut-off value
used to define low risk. However, changing
this cut-off score from 3 to 2 is not as
effective as modifying the score; the sensitiv-
ity for IRVS changes from 71% to 89% with
a cut-off of 2 (compared with 97% at a cut-
off of 3 for the modified score), and four of
38 patients who required IRVS would be
misclassified using this strategy.
There are several limitations to our study.
We only considered patients admitted to
hospital; however, it is unlikely that patients
not admitted would require IRVS. We also
included only patients meeting SIRS criteria,
and cannot exclude the possibility that
patients without SIRS initially may develop
worsening pneumonia later. This study was
limited to a single centre, albeit one with the
only ICU servicing northern Australia
between the Kimberley region in Western
Australia and the Queensland border. The
number of patients in this study meant that
we had limited statistical power to make
comparisons or perform multiple logistic
regression analysis. The high proportions of
Indigenous Australians and of patients with
hazardous levels of alcohol use mean that the
results of this study may not be generalisable
to tropical regions in other countries. We did
not collect information on antibiotic use and
thus could not control for this in our analy-
sis; however, considering our hospital uses
established antibiotic protocols with a high
level of staff compliance,7 we would not
expect this to vary between groups.
We have demonstrated that the current
SMART-COP scoring system does not ade-
quately identify patients requiring IRVS in
this tropical setting. We propose some
minor modifications that improve its per-
formance, particularly its NPV. We intend to
validate this modified scoring system pro-
spectively in patients presenting to the
emergency department at RDH.
4 Risk of needing IRVS according to SMART-COP score in the RDH cohort 
compared with (A) ACAPS cohort and (B) SMARTACOP score in the RDH cohort
Vertical dashed line indicates cut-off score for low risk (0–2). IRVS = intensive respiratory or vasopressor 
support. RDH = Royal Darwin Hospital. ACAPS = Australian Community-Acquired Pneumonia Study.5 ◆
R
eq
ui
rin
g 
IR
VS
R
eq
ui
rin
g 
IR
VS
SMART-COP
     RDH
     ACAPS
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0
SMART-COP
     RDH
SMARTACOP
     RDH
ScoreScore
A B
0        1       2       3        4       5        6        7 0        1       2       3        4       5        6        7
5 Performance characteristics of the SMART-COP score in the ACAPS and RDH 
cohorts and the SMARTACOP score in the RDH cohort
SMART-COP score  3 SMARTACOP score  3
ACAPS RDH RDH
AUROC 0.87 (0.83–0.91) 0.75 (0.66–0.83)* 0.77 (0.70–0.85) 
Sensitivity 92% (85%–97%) 71% (54%–85%)* 97% (86%–100%)
Specificity 62% (59%–66%) 69% (60%–76%) 46% (38%–54%)
PPV 22% (18%–27%) 37% (26%–50%) 32% (24%–41%)
NPV 99% (97%–99%) 91% (83%–94%)* 99% (92%–100%)
Data are shown with 95% confidence intervals. ACAPS = Australian Community-Acquired Pneumonia Study.5 
RDH = Royal Darwin Hospital. AUROC = area under the receiver operator characteristic curve. PPV = positive 
predictive value. NPV = negative predictive value. * P 0.05 compared with the ACAPS. ◆MJA • Volume 192 Number 3 • 1 February 2010 135
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6 Univariate logistic regression with need for IRVS as dependent variable
Risk factor No. (%) OR (95% CI) P
Systolic BP < 90 mmHg 9 (5%) 2.3 (1.2–4.6) 0.02
> 1 lobe involved on CXR 93 (51%) 2.6 (1.2–5.5) 0.02
Serum albumin level < 35 g/L 82 (45%) 6.8 (2.9–15.9) < 0.001
Tachypnoea 70 (38%) 1.4 (0.7–2.9) 0.34
Tachycardia 41 (22%) 1.9 (0.8–4.1) 0.13
New-onset confusion 6 (3%) 22.0 (2.5–194.4) 0.005
Hypoxaemia 49 (27%) 1.4 (0.9–2.0) 0.11
Arterial pH < 7.35 8 (4%) 2.0 (1.0–4.2) 0.05
Male 103 (56%) 1.5 (0.8–3.2) 0.23
Indigenous 120 (65%) 2.3 (1.0–5.5) 0.05
Remote-dwelling 51 (28%) 2.0 (0.9–4.2) 0.07
Homeless 17 (9%) 1.1 (0.9–1.1) 0.1
Hazardous alcohol use 76/134 (57%) 1.0 (0.9–1.2) 0.96
Chronic renal disease 33 (18%) 1.6 (0.7–3.8) 0.3
Chronic liver disease 26 (14%) 1.9 (0.8–5.8) 0.17
Diabetes mellitus 42 (23%) 0.9 (0.4–2.1) 0.8
Smoking 93/151 (62%) 0.8 (0.7–1.1) 0.08
Admitted during wet season 126 (68%) 1.0 (0.5–2.1) 0.74
COPD 39 (21%) 1.7 (0.8–3.9) 0.34
Malignancy 7 (4%) 0.6 (0.1–5.4) 0.68
IRVS = intensive respiratory or vasopressor support. OR = odds ratio. BP = blood pressure. CXR = chest x-ray. 
COPD = chronic obstructive pulmonary disease. ◆136 MJA • Volume 192 Number 3 • 1 February 2010
